Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
219. Back to Basics - Ovarian Cancer cover art

219. Back to Basics - Ovarian Cancer

219. Back to Basics - Ovarian Cancer

Listen for free

View show details
About this listen

Ovarian cancer is notoriously difficult to treat, but treatment like most cancers continue to improve. This week we discuss two pivotal immunotherapy (Keynote) trials.


KEYNOTE-826 was the first trial to show that adding immunotherapy to first-line chemotherapy helps women whose cervical cancer has come back or spread. They lived longer, and five-year results confirm the benefit lasts. KEYNOTE-A18 then moved pembrolizumab earlier, adding it to chemoradiation for newly diagnosed, high-risk disease, when the aim is cure. At three years, 82.6% of women were alive, compared with 74.8% with chemoradiation alone. Together, the two trials have made immunotherapy part of standard care across the course of this disease.


Studies Discussed in Today's Episode

KEYNOTE-826

KEYNOTE A18


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.


Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.

Hosted on Acast. See acast.com/privacy for more information.

adbl_web_anon_alc_button_suppression_t1
No reviews yet